The Apex Times
Above the Noise
Business Wire
BusinessCoca-Cola’s 2.3% yield and Nike’s 4.4% yield put dividend investors in a trade-off, analysts sayThe Apex TimesBusinessBoeing reports third-quarter delivery totals as Wall Street watches FAA approval timingThe Apex TimesBusinessMeta earnings in focus as investors weigh AI demand worries after Nasdaq weaknessThe Apex TimesBusinessDisney to absorb most of Character.AI staff after the chatbot startup’s bankruptcy filingThe Apex TimesBusinessNvidia’s November track record is strong, but one variable could disrupt the pattern, market note saysThe Apex TimesBusinessDividend debate revisits PepsiCo and Philip Morris after Philip Morris lifts quarterly payoutThe Apex TimesBusinessAlphabet investors weigh AI-chip optimism after a Wall Street call for a potential 20% upsideThe Apex TimesBusinessBroadcom (AVGO) is likely to face tough competition for advanced AI chip manufacturing capacity as TSMC ramps in 2026, according to market coverageThe Apex TimesBusinessNetflix cuts 1,000 jobs, leaving questions about what changes subscribers could actually seeThe Apex TimesBusinessIntel says Tesla will use its next-generation 14A foundry process as chip output ramps at 18A nodeThe Apex TimesBusinessVerizon rolls out new customer perks after raising prices, aiming to soften the impact for wireless usersThe Apex TimesBusinessDelta CEO outlines airfares may not fall soon, tying prices to fuel costsThe Apex TimesBusinessCoca-Cola’s 2.3% yield and Nike’s 4.4% yield put dividend investors in a trade-off, analysts sayThe Apex TimesBusinessBoeing reports third-quarter delivery totals as Wall Street watches FAA approval timingThe Apex TimesBusinessMeta earnings in focus as investors weigh AI demand worries after Nasdaq weaknessThe Apex TimesBusinessDisney to absorb most of Character.AI staff after the chatbot startup’s bankruptcy filingThe Apex TimesBusinessNvidia’s November track record is strong, but one variable could disrupt the pattern, market note saysThe Apex TimesBusinessDividend debate revisits PepsiCo and Philip Morris after Philip Morris lifts quarterly payoutThe Apex TimesBusinessAlphabet investors weigh AI-chip optimism after a Wall Street call for a potential 20% upsideThe Apex TimesBusinessBroadcom (AVGO) is likely to face tough competition for advanced AI chip manufacturing capacity as TSMC ramps in 2026, according to market coverageThe Apex TimesBusinessNetflix cuts 1,000 jobs, leaving questions about what changes subscribers could actually seeThe Apex TimesBusinessIntel says Tesla will use its next-generation 14A foundry process as chip output ramps at 18A nodeThe Apex TimesBusinessVerizon rolls out new customer perks after raising prices, aiming to soften the impact for wireless usersThe Apex TimesBusinessDelta CEO outlines airfares may not fall soon, tying prices to fuel costsThe Apex TimesBusinessCoca-Cola’s 2.3% yield and Nike’s 4.4% yield put dividend investors in a trade-off, analysts sayThe Apex TimesBusinessBoeing reports third-quarter delivery totals as Wall Street watches FAA approval timingThe Apex TimesBusinessMeta earnings in focus as investors weigh AI demand worries after Nasdaq weaknessThe Apex TimesBusinessDisney to absorb most of Character.AI staff after the chatbot startup’s bankruptcy filingThe Apex TimesBusinessNvidia’s November track record is strong, but one variable could disrupt the pattern, market note saysThe Apex TimesBusinessDividend debate revisits PepsiCo and Philip Morris after Philip Morris lifts quarterly payoutThe Apex TimesBusinessAlphabet investors weigh AI-chip optimism after a Wall Street call for a potential 20% upsideThe Apex TimesBusinessBroadcom (AVGO) is likely to face tough competition for advanced AI chip manufacturing capacity as TSMC ramps in 2026, according to market coverageThe Apex TimesBusinessNetflix cuts 1,000 jobs, leaving questions about what changes subscribers could actually seeThe Apex TimesBusinessIntel says Tesla will use its next-generation 14A foundry process as chip output ramps at 18A nodeThe Apex TimesBusinessVerizon rolls out new customer perks after raising prices, aiming to soften the impact for wireless usersThe Apex TimesBusinessDelta CEO outlines airfares may not fall soon, tying prices to fuel costsThe Apex TimesBusinessCoca-Cola’s 2.3% yield and Nike’s 4.4% yield put dividend investors in a trade-off, analysts sayThe Apex TimesBusinessBoeing reports third-quarter delivery totals as Wall Street watches FAA approval timingThe Apex TimesBusinessMeta earnings in focus as investors weigh AI demand worries after Nasdaq weaknessThe Apex TimesBusinessDisney to absorb most of Character.AI staff after the chatbot startup’s bankruptcy filingThe Apex TimesBusinessNvidia’s November track record is strong, but one variable could disrupt the pattern, market note saysThe Apex TimesBusinessDividend debate revisits PepsiCo and Philip Morris after Philip Morris lifts quarterly payoutThe Apex TimesBusinessAlphabet investors weigh AI-chip optimism after a Wall Street call for a potential 20% upsideThe Apex TimesBusinessBroadcom (AVGO) is likely to face tough competition for advanced AI chip manufacturing capacity as TSMC ramps in 2026, according to market coverageThe Apex TimesBusinessNetflix cuts 1,000 jobs, leaving questions about what changes subscribers could actually seeThe Apex TimesBusinessIntel says Tesla will use its next-generation 14A foundry process as chip output ramps at 18A nodeThe Apex TimesBusinessVerizon rolls out new customer perks after raising prices, aiming to soften the impact for wireless usersThe Apex TimesBusinessDelta CEO outlines airfares may not fall soon, tying prices to fuel costsThe Apex Times
Back to front
Jim Cramer highlighted Johnson & Johnson as its shares rose, as investors weighed a broader mixed tape
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 14, 3:24 PM EDT

Jim Cramer highlighted Johnson & Johnson as its shares rose, as investors weighed a broader mixed tape

A recent Yahoo Finance segment featuring Jim Cramer pointed to Johnson & Johnson’s (NYSE:JNJ) stock strength, noting the shares had gained roughly 5% ahead of the discussion.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Jim Cramer used Johnson & Johnson as an example of a healthcare name showing relative strength during a period when investors have been rotating across sectors, according to a Yahoo Finance post summarizing his remarks. The item states that Johnson & Johnson’s shares were up by about 5% and were among the stocks Cramer discussed.

The Yahoo Finance post frames the Johnson & Johnson mention as part of a wider set of 12 stocks that Cramer highlighted, while he also addressed other market themes tied to high-profile developments. In that context, JNJ appears less as the centerpiece of a detailed corporate update and more as a stock the TV host pointed to during a larger discussion.

Beyond the market framing, the Yahoo Finance item does not provide specific detail about what moved Johnson & Johnson shares on its own, nor does it describe any particular catalyst such as earnings results, regulatory actions, product approvals, or litigation updates. The post’s available summary focuses on the share-price change and the fact that the company was included in Cramer’s selected list.

The limited information also leaves open how investors interpreted the move. A gain of roughly 5% can reflect a range of forces, from broader risk appetite and sector flows to anticipation around upcoming company disclosures. The Yahoo Finance summary does not specify which driver, if any, was most responsible for the performance.

Johnson & Johnson operates in healthcare, a category many investors treat as a staple in portfolios because it spans areas tied to consumer health, hospital demand, and prescription medicines. Even so, without additional detail in the Yahoo Finance item, it is not possible to attribute JNJ’s move to any specific segment, product, or management action.

For now, the most actionable takeaway from the Yahoo Finance item is directional rather than fundamental: the stock’s recent strength is being spotlighted publicly in the media ecosystem. Investors watching the name may want to focus on whether the market’s interest is reinforced by forthcoming company communication, such as earnings, guidance updates, or regulatory and product announcements, rather than by television commentary alone.

As with many “stocks to watch” segments, the key limitation is what is not disclosed. The Yahoo Finance summary does not break down valuation, compare JNJ to peers, identify the precise reasons behind the share move, or provide any new company-specific information that would normally accompany an actionable thesis.

Why It Matters

  • Media spotlights like this can influence short-term retail and momentum interest, especially when framed around a clear percentage gain.
  • Because no specific operational catalyst is cited, the market may treat the move as continuation of broader trading dynamics rather than a confirmed fundamental change.
  • Investors may need to look for follow-through from company disclosures to determine whether the price action is durable.
  • The lack of detail underscores how quickly public commentary can diverge from what actually drives results in healthcare.

Sources

Key Facts

  • The Yahoo Finance post summarized Jim Cramer’s discussion of a set of 12 stocks that included Johnson & Johnson (NYSE:JNJ).
  • The summary states Johnson & Johnson shares had gained roughly 5% by the time of the discussion.
  • The item also referenced broader market themes, including Cramer’s commentary beyond JNJ, such as SpaceX’s IPO.
  • The available summary does not specify a company-specific catalyst (for example, earnings, approvals, or litigation updates).
  • The post does not provide valuation metrics or comparisons to other healthcare stocks.

Healthcare Related

Oct 18, 10:57 AM EDT
The Apex Times

Eli Lilly Shares Outperform as Investors Bet on Longevity and Pipeline Momentum

Eli Lilly (LLY) has gained about 36% over six months through October 15, according to Yahoo Finance, widening the gap versus broad-market and a commonly tracked billionaire basket. The move highlights how much near-term expectations hinge on new growth catalysts in healthcare.

Eli Lilly Shares Outperform as Investors Bet on Longevity and Pipeline Momentum
The Apex Times
Jim Cramer highlighted Johnson & Johnson as its shares rose, as investors weighed a broader mixed tape | The Apex Times